<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="23%"></col>
<col width="30%"></col>
<col width="47%"></col>
<tbody>
<tr>
<td align="center" colspan="3" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drugs That are Affected by CIPRO</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drug(s) </content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Recommendation</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Comments </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Tizanidine </paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Contraindicated</item>
</list>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Concomitant administration of tizanidine and CIPRO is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [<content stylecode="italics">see Contraindications (<linkhtml href="#ID_95cbab44-dce3-4782-84b3-8edbbb2cdfdf">4.2</linkhtml>)</content>] </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Theophylline</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Avoid Use</paragraph>
<paragraph>(Plasma Exposure Likely to be Increased and Prolonged)</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Concurrent administration of CIPRO with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#ID_da58e8c1-d5ab-438b-95df-4d1850e3853f">5.9</linkhtml>)].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Drugs Known to Prolong QT Interval</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Avoid Use</item>
</list>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>CIPRO may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#ID_1d3e625d-87bb-4f13-a26c-a9c4f0a8455e">5.11</linkhtml>) and Use in Specific Populations (<linkhtml href="#ID_d8aceab5-1590-40c3-b775-af9da631adff">8.5</linkhtml>)].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Oral antidiabetic drugs</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>Glucose-lowering effect potentiated</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Hypoglycemia sometimes severe has been reported when CIPRO and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported<content stylecode="italics">. </content>Monitor blood glucose when CIPRO is co-administered with oral antidiabetic drugs<content stylecode="italics"> [see Adverse Reactions (<linkhtml href="#ID_c56de6ea-a697-42ef-b9e5-abe3bf0fa2d1">6.1</linkhtml>)].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenytoin</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>Altered serum levels of phenytoin (increased and decreased)</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon CIPRO discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of CIPRO with phenytoin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Cyclosporine</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>(transient elevations in serum creatinine)</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Monitor renal function (in particular serum creatinine) when CIPRO is co-administered with cyclosporine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Anti-coagulant drugs</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>(Increase in anticoagulant effect)</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>The risk may vary with the underlying infection, age and general status of the patient so that the contribution of CIPRO to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co-administration of CIPRO with an oral anti-coagulant (for example, warfarin).</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Methotrexate</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels </paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant CIPRO therapy is indicated.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ropinirole</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Use with caution</item>
</list>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with CIPRO <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#ID_fa948bd8-e77d-4af4-bf01-a696ff002db4">5.16</linkhtml>)].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Clozapine</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Use with caution</item>
</list>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with CIPRO are advised.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>NSAIDs</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Use with caution</item>
</list>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Sildenafil</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>Two-fold increase in exposure</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Monitor for sildenafil toxicity <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#ID_732dd173-ef1d-4617-8b08-1af37957ef6c">12.3</linkhtml>
</content>)<content stylecode="italics">]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Duloxetine</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Avoid Use</paragraph>
<paragraph>Five-fold increase in duloxetine exposure</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>If unavoidable, monitor for duloxetine toxicity </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Caffeine/Xanthine Derivatives</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>Reduced clearance resulting in elevated levels and prolongation of serum half-life</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>CIPRO inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary.</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Drug(s) Affecting Pharmacokinetics of CIPRO</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx<sup>®</sup> (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph> CIPRO should be taken at least two hours before or six hours after Multivalent cation-containing products administration <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#ID_c96e914f-a96f-4205-8e1d-590aac9ffad3">2.4</linkhtml>)].</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Decrease CIPRO absorption, resulting in lower serum and urine levels </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Probenecid</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>(interferes with renal tubular secretion of CIPRO and increases CIPRO serum levels)</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<paragraph>Potentiation of CIPRO toxicity may occur.</paragraph>
</td>
</tr>
</tbody>
</table>